396 related articles for article (PubMed ID: 29902678)
21. Long non-coding RNA urothelial carcinoma-associated 1 as a tumor biomarker for the diagnosis of urinary bladder cancer.
Wang Z; Wang X; Zhang D; Yu Y; Cai L; Zhang C
Tumour Biol; 2017 Jun; 39(6):1010428317709990. PubMed ID: 28639914
[TBL] [Abstract][Full Text] [Related]
22. DD23 Biomarker: a prospective clinical assessment in routine urinary cytology specimens from patients being monitored for TCC.
Sawczuk IS; Pickens CL; Vasa UR; Ralph DA; Norris KA; Miller MC; Ng AY; Grossman HB; Veltri RW
Urol Oncol; 2002; 7(5):185-90. PubMed ID: 12644214
[TBL] [Abstract][Full Text] [Related]
23. Measurements of complement factor H-related protein (BTA-TRAK assay) and nuclear matrix protein (NMP22 assay)--useful diagnostic tools in the diagnosis of urinary bladder cancer?
Mahnert B; Tauber S; Kriegmair M; Nagel D; Holdenrieder S; Hofmann K; Reiter W; Schmeller N; Stieber P
Clin Chem Lab Med; 2003 Jan; 41(1):104-10. PubMed ID: 12636058
[TBL] [Abstract][Full Text] [Related]
24. Predictive value of MCM5 (ADXBLADDER) analysis in urine of men evaluated for the initial diagnosis of bladder cancer: A comparative prospective study.
Anastasi E; Maggi M; Tartaglione S; Angeloni A; Gennarini G; Leoncini PP; Sperduti I; Di Lascio G; De Stefano V; Di Pierro GB; Del Giudice F; Busetto GM; De Berardinis E; Sciarra A
Diagn Cytopathol; 2020 Nov; 48(11):1034-1040. PubMed ID: 32562513
[TBL] [Abstract][Full Text] [Related]
25. Patients with a negative cystoscopy and negative Nmp22® Bladderchek® test are at low risk of missed transitional cell carcinoma of the bladder: a prospective evaluation.
Terrell JD; Elias KJ; Sagalowsky AI; Lotan Y
Int Braz J Urol; 2011; 37(6):706-11. PubMed ID: 22234001
[TBL] [Abstract][Full Text] [Related]
26. A urinary assay for mutation and methylation biomarkers in the diagnosis and recurrence prediction of non-muscle invasive bladder cancer patients.
Huang H; Liu A; Liang Y; Xin Y; Liu J; Hao Y; Huang D; Chen L; Li W; Jiang G; Huang Y; Xu Y; Zhang J; Ma T; Xu D; Gao Y
BMC Med; 2023 Sep; 21(1):357. PubMed ID: 37726806
[TBL] [Abstract][Full Text] [Related]
27. Urinary Biomarkers for Diagnosis of Bladder Cancer: A Systematic Review and Meta-analysis.
Chou R; Gore JL; Buckley D; Fu R; Gustafson K; Griffin JC; Grusing S; Selph S
Ann Intern Med; 2015 Dec; 163(12):922-31. PubMed ID: 26501851
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic evaluation of urinary angiogenin (ANG) and clusterin (CLU) as biomarker for bladder cancer.
Shabayek MI; Sayed OM; Attaia HA; Awida HA; Abozeed H
Pathol Oncol Res; 2014 Oct; 20(4):859-66. PubMed ID: 24696417
[TBL] [Abstract][Full Text] [Related]
29. Methylation study of the Paris system for reporting urinary (TPS) categories.
Pierconti F; Martini M; Cenci T; Fiorentino V; Sacco E; Bientinesi R; Pugliese D; Iacovelli R; Schinzari G; Larocca LM; Bassi PF
J Clin Pathol; 2021 Feb; 74(2):102-105. PubMed ID: 32527754
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder.
Sözen S; Biri H; Sinik Z; Küpeli B; Alkibay T; Bozkirli I
Eur Urol; 1999 Sep; 36(3):225-9. PubMed ID: 10450007
[TBL] [Abstract][Full Text] [Related]
31. Can urinary biomarkers replace cystoscopy?
Maas M; Bedke J; Stenzl A; Todenhöfer T
World J Urol; 2019 Sep; 37(9):1741-1749. PubMed ID: 30283995
[TBL] [Abstract][Full Text] [Related]
32. Urinary protein biomarker panel for the detection of recurrent bladder cancer.
Rosser CJ; Chang M; Dai Y; Ross S; Mengual L; Alcaraz A; Goodison S
Cancer Epidemiol Biomarkers Prev; 2014 Jul; 23(7):1340-5. PubMed ID: 24714076
[TBL] [Abstract][Full Text] [Related]
33. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer.
Mowatt G; Zhu S; Kilonzo M; Boachie C; Fraser C; Griffiths TR; N'Dow J; Nabi G; Cook J; Vale L
Health Technol Assess; 2010 Jan; 14(4):1-331, iii-iv. PubMed ID: 20082749
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer.
Gilbert SM; Veltri RW; Sawczuk A; Shabsigh A; Knowles DR; Bright S; O'Dowd GJ; Olsson CA; Benson MC; Sawczuk IS
Urology; 2003 Mar; 61(3):539-43. PubMed ID: 12639642
[TBL] [Abstract][Full Text] [Related]
35. Multi-institutional external validation of urinary TWIST1 and NID2 methylation as a diagnostic test for bladder cancer.
Fantony JJ; Abern MR; Gopalakrishna A; Owusu R; Jack Tay K; Lance RS; Inman BA
Urol Oncol; 2015 Sep; 33(9):387.e1-6. PubMed ID: 26027762
[TBL] [Abstract][Full Text] [Related]
36. [Non-invasive urinary diagnosis of bladder cancer. What do we know?].
Kausch I; Böhle A
Urologe A; 2003 Jul; 42(7):912-21. PubMed ID: 12898034
[TBL] [Abstract][Full Text] [Related]
37. Current status of genetic urinary biomarkers for surveillance of non-muscle invasive bladder cancer: a systematic review.
Lozano F; Raventos CX; Carrion A; Trilla E; Morote J
BMC Urol; 2020 Jul; 20(1):99. PubMed ID: 32664878
[TBL] [Abstract][Full Text] [Related]
38. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow-up of non-muscle-invasive bladder cancer: a blinded prospective multicentric study.
Gontero P; Montanari E; Roupret M; Longo F; Stockley J; Kennedy A; Rodriguez O; McCracken SRC; Dudderidge T; Sieverink C; Vanié F; Allasia M; Witjes JA; Sylvester R; Colombel M; Palou J
BJU Int; 2021 Feb; 127(2):198-204. PubMed ID: 32745350
[TBL] [Abstract][Full Text] [Related]
40. Urine markers for detection and surveillance of bladder cancer.
Xylinas E; Kluth LA; Rieken M; Karakiewicz PI; Lotan Y; Shariat SF
Urol Oncol; 2014 Apr; 32(3):222-9. PubMed ID: 24054865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
